Methocarbamol in Ventral and Inguinal HR

• Status: Not yet recruiting
• Trial end date: 2025-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to gather information on methocarbamol as a pain management treatment for ventral or inguinal hernia repair.

Methocarbamol has been part of the pain management treatment for both inpatient and outpatient procedures at Prisma Health. This study will compare the outcomes of patients who receive methocarbamol, those who receive the standard opioid pain management treatment, and those who receive methocarbamol plus the standard opioid pain management treatment.

Participants will be randomized into one of the study groups listed below.

Primary ventral hernia repair or inguinal hernia repair:

Group 1: standard opioid after surgery Group 2: methocarbamol after surgery

Open or robotic ventral hernia repair outpatient:

Group 1: standard opioid after surgery Group 2: standard opioid plus methocarbamol after surgery

Open or robotic ventral hernia repair inpatient:

Group 1: standard opioid at discharge Group 2: standard opioid plus methocarbamol at discharge

A total of 120 participants will be included in the study.

Participation will last for about 7 days after surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prisma Health-Upstate
• Treatments: Analgesics, Opioid; Methocarbamol

Criteria

Inclusion Criteria:

>18 y/o Patients undergoing open primary ventral hernia repair (group 1) Patients undergoing inguinal hernia repair (open, laparoscopic, or robotic; group 2) Patients undergoing open incisional hernia repair (group 3) Robotic repair ventral or incisional hernias (group 4) Given consent for randomization

Exclusion Criteria:

<18 y/o Pregnancy Chronic opioid users